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Functional mitral regurgitation which deteriorates hemody-
amics often develops in patients with systolic heart failure.
he functional mitral regurgitation is associated with poor prog-
osis and is tried to be treated with surgical interventions or
rans-catheter interventions [1]. On the other hand, cardiac resyn-
hronization therapy (CRT) is well established for the standard
reatment of heart failure [2]. In addition, there are studies show-
ng that CRT may  improve functional mitral regurgitation. Although
he guidelines [3] suggest the most suitable candidates for CRT are
atients with electrocardiogram of “wide QRS complex more than
50 ms  and left bundle branch block morphology”, a considerable
umber of patients showed no response to the therapy. Thus, the
ndividual prediction of the effect of CRT is still under discussion.
The study concerning the relation between heart rate and prog-
osis of heart failure [4] suggested that lowering the heart rate
ay  improve the prognosis of heart failure. Although lowering
eart rate is not a sole mechanism of beta-blocker therapy because
arvedilol which has a less negative chronotropic effect than biso-
rolol [5] is more effective in improvement of prognosis of heart
ailure with beta-blocker therapy [6,7], the effect of beta-blocker
reatment for heart failure relates to the decrease in heart rate [8].
he sub-analysis of the SHIFT study [9] showed that the most effec-
ive group was heart failure with tachycardia. The more the heart
ate decreases during treatment for acute heart failure, the better
he prognosis of heart failure [10]. These studies created the myth
f heart rate: “the lower the better”.
We should keep in mind that the increase in heart rate in heart
ailure is a compensatory mechanism for maintaining the hemody-
amics, since heart rate is an important factor for increasing cardiac
utput.
Chikata et al. [11] presented an interesting case of heart failure
hat showed hemodynamic improvement by atrial pacing in this
ssue of the journal. According to the previous studies concerning
eart failure treatment as mentioned above, this case might have
een expected to be improved by CRT, because CRT might have
aused reverse remodeling and decrease in functional mitral regur-
itation [12]. However, atrial pacing rather than CRT improved the
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ttp://dx.doi.org/10.1016/j.jccase.2013.11.003hemodynamics unexpectedly. Although CRT is a standard therapy
for heart failure, its effect is not completely predictable because
the effect may  vary depending on the position of the lead and pat-
tern of dyssynchrony – electrical or contractile. In general, CRT is
less effective in ischemic cardiomyopathy than idiopathic dilated
cardiomyopathy [13]. In addition, the mechanism of functional
mitral regurgitation may  vary depending on the global and regional
remodeling and distortion of the components of the mitral valve
[14].
The increase in heart rate by atrial pacing caused the dramatic
improvement in hemodynamics in this case. It was noteworthy
that the patient did not show tachycardia, as this report described
that the heart rate at admission was 60 bpm, although the patient
was admitted because of decompensated acute heart failure. Inap-
propriate bradycardia may  worsen heart failure in the depressed
left ventricle, although bradycardia alone does not cause heart fail-
ure as long as the left ventricular function is normal. To maintain
cardiac output in systolic dysfunction, there are two major com-
pensatory mechanisms, that is, increase in heart rate and increase
in stroke volume. To maintain stroke volume, left ventricular vol-
ume  should be increased in the face of diminished ejection fraction.
In this case, left ventricular end-diastolic dimension was  60 mm,
which might not be large enough and heart rate was  only 60 bpm
in congestive heart failure, suggesting inadequate compensatory
mechanisms. The akinetic inferior wall might produce deformity of
left ventricular geometry causing tethering of mitral valve complex.
The electrocardiogram in this case showed that the duration
of QRS complex was 120 ms  and the morphology of QRS  complex
was not typical left bundle branch block where there was tall R′
wave instead of S wave in V1 lead. The effect of CRT was far less
remarkable in patients with QRS duration between 120 ms and
150 ms  than those with QRS duration more than 150 ms [15]. This
may suggest the ineffectiveness of CRT in this patient. The CRT
could improve the electrical dyssynchrony but not the contractile
dyssynchrony in a left ventricle composed of a mixture of normal
and infarcted or ischemic myocardium. The ventricular pacing
may  worsen the propagation of the electrical impulse rather than
the orthodromic atrio-ventricular conduction.
The authors showed that the atrial pacing alone decreased V
wave of pulmonary capillary wedge pressure more than the biven-
tricular pacing. The improvement in functional mitral regurgitation
was probably caused by the increase in heart rate with atrial pac-
ing. The increase in heart rate by atrial pacing resulted in increase in
cardiac output causing the decrease in left atrial pressure and the
decrease in left ventricular size or mitral annulus, which in turn
resulted in the reduction of mitral regurgitation. As the authors
vier Ltd. All rights reserved.
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entioned, the optimal heart rate may  vary among individual
atients depending on left ventricular systolic function, geometry,
nd diastolic function. We  have to keep in mind that we  cannot
pply directly the result of a large-scale study to an individual case
ithout questioning whether there are some variant characteris-
ics, although a large-scale study is useful to clarify the scientiﬁc and
tatistical effects of the intervention. The clinician may  be required
o be able to detect and observe such variant clinical ﬁndings from
ach individual patient.
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